Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
Center for Beta Cell Therapy in Diabetes from Jette, company number BE0872566468, closed financial year 2025 with a result of € -219,285 after tax. For that financial year Center for Beta Cell Therapy in Diabetes recorded a gross margin of € -184,400 and equity of € 2.6 million. Compared with financial year 2024, the result moved from € -128,261 to € -219,285. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.
€ 2.6 million
▼ 8% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -219,285
▼ 71 % more loss than in 2024
Profit after tax over the fiscal year.
€ 141,200
▼ 67% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
0.1
Average over the fiscal year, from the social balance sheet.
€ 18,023
▼ 13% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 6,517
▼ 91% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 2,371
▲ 2% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -205,870 | € -199,826 | € -93,338 | € -184,400 | ▼ € 91,062 |
| Profit after taxes | € -520,242 | € -17,601 | € -128,261 | € -219,285 | ▼ € 91,024 |
| Equity | € 2,989,677 | € 2,972,076 | € 2,843,815 | € 2,624,530 | ▼ 8% |
| Total debts | € 269,285 | € 277,719 | € 474,193 | € 536,297 | ▲ 13% |
| Cash | € 745,488 | € 679,793 | € 425,699 | € 141,200 | ▼ 67% |
| Retained profit | € 933,783 | € 916,182 | € 787,921 | € 568,637 | ▼ 28% |
| Balance sheet total | € 3,258,961 | € 3,249,794 | € 3,318,008 | € 3,160,827 | ▼ 5% |
| Employees (FTE) | 0.2 | 0.2 | 0.1 | 0.1 |
Key figures of Center for Beta Cell Therapy in Diabetes, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Center for Beta Cell Therapy in Diabetes?
What happened at Center for Beta Cell Therapy in Diabetes in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 219,285. Source: NBB ↗
- New establishment in Jette. KBO
- Start of the company according to the CBE. KBO
In short
From € 520,242 loss in 2022 to € 219,285 loss in 2025.
A new publication or filing at Center for Beta Cell Therapy in Diabetes? We notify you, reason included.
Follow Center for Beta Cell Therapy in DiabetesDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Center for Beta Cell Therapy in Diabetes are Bart Keymeulen, Daniël Pipeleers and Sabrina Uyttenhove. Daniël Pipeleers is also behind OPUS, BETA - CELL and Drs Pipeleers & Marichal. Sabrina Uyttenhove is also behind OPUS.
Directors
According to the 2025 annual accounts
Bart Keymeulen
Director
Establishments
Establishment units
Physical locations of this company
Laarbeeklaan 103
1090 Jette
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0872.566.468
- VAT number
- BE 0872.566.468
- Registered office
- Laarbeeklaan 103, 1090 Jette
- Names & denominations
- Center for Beta Cell Therapy in Diabetes
- Enterprise type
- Rechtspersoon
- Legal form
- Non-profit association
- Legal situation
- Normale toestand
- Start date
- 17 March 2005
- Peppol
- Active · Active since 17 Dec 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied